The drug manufacturer states that the Health Officials has recently accepted and supported a daily HIV prevention pill, combining with safer sexual lives.
On Monday, Gilead Sciences Canada announced that its once-daily pill, which contains two anti-HIV drugs, had been approved in that country in order to plummet the risk of HIV infection through sexual transmissions.
Gilead Sciences, the vice-president of Gilead’s Research and Development department stated that that company was extremely pleased to provide that HIV – prevention tool to Canadian people who were at risk of being contracted.
According to Sean Hosein from CATIE (Canada’s Source for HIV and HEP C Information), the act of taking medicines to lower the possibility of getting infected by HIV virus of HIV-negative people is so-called pre-exposure prophylaxis (PrEP).
While approving the use of truvada to prevent HIV, Canadian Health Officials has also pointed out that before starting using that kind of drug, people have to test for HIV first. Also, they need to screen for, and sometimes, treatment of HIV-infected cases through sexual transmission. During the time using truvada, they have to test for HIV regularly, as well as use condoms while having sex.
Truvada is said to cost around $1000 per month.
Hosein indicated that their insurance companies, their provinces and territories need to talk together to work out a prevention strategy, including truvada.
A study published last year in the New England Journal of Medicine, the use of medications was proved to link to the rising rates of nausea, diarrhea, vomiting and abdominal pain (up to 14 percent), in comparison with 5 percent of placebo. The drug is also associated with higher percentage of Kidney side-effects, with 18 percent.
According to Dr. Isaac Bogoch, who is an infectious disease clinician and researcher at Toronto’s University Health Network, the demand for pre-exposure prophylaxis (PrEP) is high when Canadian people is on anti-HIV clinics.
He said that people, who are in need of HIV prevention care, have no reason to be seen in the hospital. Hence, this kind of care should be carried out right in the community so as to keep the confidentiality for patients.
The next step of that strategy was to increase the accessibility, broaden it through families, Bogoch commented.
The physicians will strictly follow the guidelines and take care of people who use PrEP while other one who are already infected by HIV will receive the appropriate treatment instead. These practices, therefore, would lower the potential of drug-resistant HIV.